Candesartan in the prevention of migraine
Candesartan in migraine prophylaxis
- candesartan is the most studied angiotensin receptor blocker (ARB) in the role as a migraine prophylaxis (1):
- data from 2 randomised controlled trials suggest that around 40% of patients taking 16 mg per day of candesartan will have a clinically significant reduction in their number of headache days per month
- candesartan for migraine prophylaxis has several advantages (1):
- typically well tolerated, although it does require monitoring of electrolyte levels, serum creatinine level, and hypotensive symptoms
- an excellent option for patients who have additional comorbidities such as hypertension, cardiovascular disease, or chronic kidney disease
- may not be as effective as other first-line options such as amitriptyline or metoprolol (although data from head-to-head trials are sparse) (1)
Randomised controlled trial evidence (episodic migraine)
- a study (n = 534) found candesartan 16 mg daily resulted in a reduction in the mean number of migraine days by weeks 9 to 12 (from a baseline of 5.7 days) compared with placebo (decrease of 2.04 days vs 0.82 days; difference -1.22 [95% CI -1.75 to -0.70]; p < 0.0001) and was well tolerated (2)
Real-world effectiveness and tolerability (chronic and treatment-resistant migraine)
- a retrospective cohort study (n = 120; 70% with chronic migraine, 42.7% with medication-overuse headache, median of 3 prior prophylactic treatments) evaluated candesartan in routine headache clinic practice (3):
- mean monthly headache days decreased from 20.5 at baseline by 4.3 days at 3 months (weeks 8 to 12; p < 0.001) and by 4.7 days at 6 months (weeks 20 to 24; p < 0.001) (3)
- a 50% or greater reduction in monthly headache days was achieved in 32.5% of patients at 3 months and 31.7% at 6 months, with treatment retention rates of 85.0% and 58.3%, respectively
- discontinuation due to adverse effects occurred in 18.3% of patients, most commonly light-headedness (5.0%) and hypotension (4.2%)
- a higher number of prior prophylactic treatments (odds ratio [OR] 0.79 per prior drug; 95% CI 0.64 to 0.97) and the presence of daily headache (OR 0.39; 95% CI 0.16 to 0.97) were associated with a lower probability of response (3)
Dosing and serum concentration relationships
- a prospective observational cohort study (MigriNor study; n = 166 adults with episodic or chronic migraine using flexible candesartan dosing) examined dose titration and serum concentration-response relationships over 12 weeks (4):
- no significant differences in adverse drug reactions or treatment acceptability were observed between starting doses of 4 mg and 8 mg, suggesting that an 8 mg starting dose may be preferable in practice (4)
- substantial interindividual variability in serum candesartan concentrations was observed across dose levels
- higher serum candesartan concentrations were associated with lower odds of experiencing headache days (OR 0.97 per 10 nmol/L increase; 95% CI 0.96 to 0.98; p < 0.001) and migraine days (OR 0.98 per 10 nmol/L increase; 95% CI 0.97 to 0.99; p = 0.005) (4)
- serum concentration was not significantly associated with adverse drug reactions (OR 0.94 per 10 nmol/L; p = 0.066) or overall treatment acceptability, supporting individualised dose titration according to clinical response and tolerability
Reference:
- Crawley A, Myers J, Regier LD. Clinical pearls for management of migraines. Can Fam Physician. 2024 May;70(5):325-327.
- Oie RL et al. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurology 2025; 24 (10): 817-27.
- Sanchez-Rodriguez C, Sierra A, Planchuelo-Gomez A, et al. Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. Sci Rep. 2021;11:3846.
- Riise HS, Simpson M, Espnes KA, et al. Serum Concentration Relationships of Candesartan in Migraine Prevention. Basic Clin Pharmacol Toxicol. 2026;139:e70322.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.